,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2023', 'fs': 'Jan 2023', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkS2AS'}, 'Id': 'a0POZ000004AfkS2AS', 'Event_Date__c': '2023-01-23', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jan 2023', 'Status_History__c': 'a132P000000EDQxQAO'}, 'change': None}]",Jan 2023,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkT2AS'}, 'Id': 'a0POZ000004AfkT2AS', 'Event_Date__c': '2023-03-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDTpQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'fs': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkU2AS'}, 'Id': 'a0POZ000004AfkU2AS', 'Event_Date__c': '2023-05-23', 'Event_Description__c': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EDzyQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that sirolimus be listed with a <strong>high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for life for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1. Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2. Patient has ongoing improvement in symptoms </span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>11.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee recommendation was based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of those with facial angiofibromas</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of other treatments available in the public system</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The need to ensure equitable access to treatment</p><p><br></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that sirolimus be listed with a <strong>high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for life for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1. Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2. Patient has ongoing improvement in symptoms </span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>11.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee recommendation was based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of those with facial angiofibromas</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of other treatments available in the public system</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The need to ensure equitable access to treatment</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the impact of funding sirolimus for the treatment of facial angiofibromas associated with tuberous sclerosis complex on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that whilst there was no published evidence on the prevalence of the condition in Māori, approximately four of the 32 requests for access to sirolimus, for all indications, via the Named Patient Pharmaceutical Assessment (NPPA) process were for Māori. The Committee noted access to medicines via the NPPA process may result in inequitable access due to the physician time and resource required for an application.</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted its previous review (as the Dermatology Subcommittee) in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a> of an application for topical sirolimus consequent to NPPA applications for sirolimus ointment (rapamycin). That application involved a 0.1-1% ointment that was compounded by Optimus Healthcare compounding pharmacy. The Committee noted that the recommendation of deferral, subject to the outcome of a phase two study by Koenig et al on 177 patients with tuberous sclerosis complex associated facial angiofibromas treated with topical sirolimus (NCT01526356). This product was ranked in 2020. This application is now on the decline list due to the lack of a supplier, and the product not being able to be safely compounded in community pharmacy.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a further application for this pharmaceutical was received in January 2023, from a supplier for the same indication, but for a non-compounded product with a strength of 0.5%.</p><p><br></p><p><em>Health need</em></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need of those with facial angiofibromas associated with tuberous sclerosis complex in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted facial angiofibromas are the most common presentation in tuberous sclerosis complex and are prevalent in 70-80% of those with the condition.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted tuberous sclerosis complex is an autosomal dominant genetic disorder which is caused by a mutation in either the TSC1 gene or the TSC2 gene. It is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the prevalence of tuberous sclerosis complex is estimated at between 0.7 – 8.8 per 100,000, and facial angiofibromas to be the most common presentation in tuberous sclerosis complex which are prevalent in 70-80% of people with tuberous sclerosis complex. The Committee noted in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>, that there could be 399 individuals in New Zealand with tuberous sclerosis complex (based on a 2004 estimate), and of that number, there may be 40-80 individuals in New Zealand with moderate/significant facial angiofibromas, with an additional seven new cases per year.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted those with facial angiofibromas associated with tuberous sclerosis complex can experience frequent spontaneous and uncontrolled bleeding, and infections are common when the lesions are present around the eyes, nose, and mouth. Due to progressive growth, over time facial angiofibromas can impair vision and breathing, and have psychological consequences (emotional, social and self-image disorders), with uncontrolled growth potentially causing further cosmetic disfigurement (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. Pediatr Dermatol. 2016; 33:518-25</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the number and size of the facial angiofibromas increased through childhood, whilst in adulthood the lesions tended to be stable or grow at a slower rate.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the effects of the condition were most distressing in young adults, and as such they had a higher health need.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a 2016 survey, undertaken in a children’s hospital, suggested that those who received treatment for facial angiofibromas reported a significantly improved Children’s Dermatology Life Quality Index (CDLQI) score compared to those not treated. The CDLQI score of untreated individuals was 9.5 compared to 3.83 in those who had received treatment (p=0.001). Those who were not treated had a CDLQI score that represented a moderate effect on quality of life, whilst those treated had a small effect (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).The largest proportion of those who were treated had been recommended to use topical rapamycin (47.3%) (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a US study provided by the supplier that reported gaps in the care for people with facial angiofibromas associated with tuberous sclerosis complex. 41% of people reported never receiving treatment for facial angiofibromas even though 74.3% had visited a dermatologist, indicating many people are unable to receive treatment. The Committee considered that underdiagnosis may also influence access to treatment in New Zealand for those affected, with the condition being hard to diagnose.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there is minimal access to dermabrasion or laser therapies in the public health system, these treatments must be self-funded by the individual at significant cost.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the health need of those with facial angiofibromas was higher than those on the body due to increased prominence of the angiofibromas, and the ensuing greater cosmetic impact.</p><p><br></p><p><em>Health benefit</em></p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus forms a complex which binds to and selectively inhibits mTORC1. The mTOR complex modulates aspects of the cell cycle, cell growth, proliferation and migration. mTORC1 inhibition reduces the dysregulated growth and differentiation observed in facial angiofibromas.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800048/"" target=""_blank"">Koenig et al, JAMA Dermatol. 2018;154:773-80</a> study of 179 individuals randomised to control, 0.1% or 1% topical treatment for 6 months, applied once daily. At 6 months the Angiofibroma Grading Scale mean improvement for 1% sirolimus was 16.7 points vs 11.0 for 0.1% sirolimus vs 2.1 points for vehicle only (P &lt; .001 for 1% and 0.1% vs vehicle only). The Committee noted there were minimal adverse events. The Committee considered most improvement was observed in the first month of treatment, with most participants completing the trial. The Committee noted there was no drug detected in the serum of individuals.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>Committee noted the <a href=""https://pharmconnect.lightning.force.com/lightning/r/Application__c/a0S2P0000032osgUAA/view"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2017;153:39-48</a> study that involved 36 people, of which 18 were children. Sirolimus gel concentrations of 0.05%, 0.1%, or 0.2% or placebo were applied twice daily for 12 weeks. The improvement factor was statistically significant in all active treatment groups receiving 0.2% sirolimus (mean [SD], 1.94 [0.68]; P &lt; .001) but not in the adult subgroups receiving 0.1% (mean [SD], 0.88 [0.85]; P = .31) and 0.05% (mean [SD], 1.63 [1.11]; P = .09) concentrations of sirolimus. No significant adverse effects were observed. The Committee considered that whilst the study was small, it was well designed.</p><p>11.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that low blood levels of sirolimus (&lt;0.25 ng/mL) were detected in adults (1 [25%] in 0.1% and 2 [50%] in 0.2%) and children (1 [25%] in 0.05%, 2 [50%] in 0.1%, and 4 [100%] in 0.2%). The Committee noted that the authors considered this may be due to the gel formulation being better absorbed than the ointment form.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800026/"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2018;154:781-788</a> study of 62 people, of which 27 were children, who were received either 0.2% sirolimus gel (n=30) or placebo (n=32) applied twice daily for 12 weeks. The response rates of the angiofibromas at weeks 4, 8, and 12 of treatment was 20% (95% CI, 8%-39%; P = .01), 43% (95% CI, 26%-63%; P &lt; .001), and 60% (95% CI, 41%-77%; P &lt; .001) with sirolimus vs 0% in placebo group. 0/ 31 in placebo group were rated improved or better, and 26 (84%) were rated unchanged. In the sirolimus group 5 (17%) and 13 (43%) were rated markedly improved and improved, respectively.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22309333/"" target=""_blank"">Foster et al, Australas J Dermatol. 2012;53:52-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692771/"" target=""_blank"">Wataya-Kaneda et al, Br J Dermatol. 2011;165:912-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Csoma et al, Pediatric Dermatology. 2019;36:S41-S42 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29270462/"" target=""_blank"">Amin et al, Int Sch Res Notices. 2017:8404378</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24359523/"" target=""_blank"">Tu et al, Australas J Dermatol. 2014;55:63-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21834948/"" target=""_blank"">Salido et al, J Eur Acad Dermatol Venereol. 2012;26:1315-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763637/"" target=""_blank"">Viswanath et al, Indian J Dermatol. 2016; 61: 119</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24136238/"" target=""_blank"">Bae-Harboe et al, Lasers Surg Med. 2013;45:555-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24355193/"" target=""_blank"">Knopfel et al, Actas Dermosifiliogr. 2014;105:802-3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Smith et al, BJD, 2012; 167 (s1); ppl127-141 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ott et al, Int J Clin Pharm, 2013, 35;1331 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23680945/"" target=""_blank"">Wheless et al, J Child Neurol, 2013, 28;933</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/"" target=""_blank"">Wheeless et al, Child Neurol Open. 2019; 6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22301052/"" target=""_blank"">Truchuelo et al, Dermatol Online J. 2012;18:15</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22250258/"" target=""_blank"">Wataya-Kaneda et al, Arch Dermatol. 2012;148:138-9</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21931059/"" target=""_blank"">DeKlotz et al, Arch Dermatol. 2011;147:1116-7</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20644030/"" target=""_blank"">Haemel et al. Arch Dermatol. 2010;146:715-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ejhp.bmj.com/content/23/Suppl_1/A207.2"" target=""_blank"">Trujillano Ruiz et al, EJH Pharmacy 2016;23:A207. </a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987392/"" target=""_blank"">Okanishi et al, Front Med (Lausanne). 2020; 7: 1.</a></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-family: Symbol;"">·</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"">Lee et al, Dermatology. 2018;234:13-22</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01417-5"" target=""_blank"">Hatano et al, Orphanet J Rare Dis. 2020;15:133</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32385845/"" target=""_blank"">Wataya-Kaneda et al, Dermatol Ther (Heidelb). 2020;10:635-650</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28181194/"" target=""_blank"">Ebrahimi-Fakhari et al, Dermatol Ther (Heidelb), 2017; 7:175–179</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29380350/"" target=""_blank"">Norrenberg et al, Br J Dermatol. 2018;179:208-209</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Safa et al, Oxford Medical Case Reports, 2017;7, 104–105 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28771801/"" target=""_blank"">Wang et al, Pediatr Dermatol. 2017;34:572-577.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23909960/"" target=""_blank"">Tanaka et al, Br J Dermatol. 2013;169:1314-8.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27643542/"" target=""_blank"">Cinar et al, Indian J Dermatol Venereol Leprol. 2017;83:27-32</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25790347/"" target=""_blank"">Pynn et al, Pediatr Dermatol. 2015;32:e120-3.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Hwang et al, Journal of Dermatology, 2012 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372909/"" target=""_blank"">Vasani et al, Indian J Dermatol. 2015; 60: 165–169.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24401865/"" target=""_blank"">Park et al, Dermatology 2014;228:37–41:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Rodrigo-Nicolas et al, J Am Acad Dermatol, 2013, P6521 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20673154/"" target=""_blank"">Kaufman Mcnamara et al, J Dermatolog Treat. 2012; 23: 46–48</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21861956/"" target=""_blank"">Valerón-Almazán P, et al, Actas Dermosifiliogr. 2012;103:165—6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28502378/"" target=""_blank"">Malissen et al, J Am Acad Dermatol. 2017;77:464-472.e3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692776/"" target=""_blank"">Mutizwa et al, Br J Dermatol. 2011;165:922-3</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32064596/"" target=""_blank"">Chen et al Br J Dermatol. 2020; 183:655-663</a></p><p>1.21.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered there to be a lack of long-term safety data (&gt;5 years) regarding the adverse effects of topical sirolimus.\xa0</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered it was unclear which types of lesions respond to topical sirolimus, but facial hypomelanotic macules and some fibrous cephalic plaques have been observed to respond to treatment.</p><p><br></p><p><em>Suitability</em></p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus is administered as a topical preparation, once daily, ideally prior to sleep. The amount of topical preparation that needs to be applied is 6 mg/cm2/day to produce a thin confluent layer on the affected skin. The recommended amount should be explained by a pharmacist or prescriber to ensure that an adequate amount is administered.</p><p><br></p><p><em>Cost and savings</em></p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that individuals were likely to need long term uninterrupted treatment to maintain the clinical benefit, with the Committee noting the condition had a lifelong health need. In practical use the Committee estimated that many people will cease use as their condition improves, restarting after a period off treatment as the condition recurs. The Committee estimated an average time on treatment as 50% across the entire group of people using sirolimus for facial angiofibromas.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the quantity of ointment used per week would be equal to their previous estimate for the 0.1% formulation, at 1-2g used per week. They considered that due to the higher strength, there is likely an efficacy gain over the 0.1% formulation.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted health benefit evidence that reported a reduction in application frequency from three times weekly to once weekly did not adequately address the health needs of the individual, with the condition worsening upon reduction in treatment.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that while some people would receive surgical treatment privately, this was uncommon in the public system.</p><p><br></p><p><em>Funding criteria</em></p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that funding of this treatment through the NPPA pathway should not be restricted during the funding assessment process.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for sirolimus if it were to be funded in New Zealand for facial angiofibromas associated with tuberous sclerosis complex. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AfkX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000czFN"" alt=""image.png""></img></p>', 'fs': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the impact of funding sirolimus for the treatment of facial angiofibromas associated with tuberous sclerosis complex on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that whilst there was no published evidence on the prevalence of the condition in Māori, approximately four of the 32 requests for access to sirolimus, for all indications, via the Named Patient Pharmaceutical Assessment (NPPA) process were for Māori. The Committee noted access to medicines via the NPPA process may result in inequitable access due to the physician time and resource required for an application.</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted its previous review (as the Dermatology Subcommittee) in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a> of an application for topical sirolimus consequent to NPPA applications for sirolimus ointment (rapamycin). That application involved a 0.1-1% ointment that was compounded by Optimus Healthcare compounding pharmacy. The Committee noted that the recommendation of deferral, subject to the outcome of a phase two study by Koenig et al on 177 patients with tuberous sclerosis complex associated facial angiofibromas treated with topical sirolimus (NCT01526356). This product was ranked in 2020. This application is now on the decline list due to the lack of a supplier, and the product not being able to be safely compounded in community pharmacy.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a further application for this pharmaceutical was received in January 2023, from a supplier for the same indication, but for a non-compounded product with a strength of 0.5%.</p><p><br></p><p><em>Health need</em></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need of those with facial angiofibromas associated with tuberous sclerosis complex in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted facial angiofibromas are the most common presentation in tuberous sclerosis complex and are prevalent in 70-80% of those with the condition.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted tuberous sclerosis complex is an autosomal dominant genetic disorder which is caused by a mutation in either the TSC1 gene or the TSC2 gene. It is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the prevalence of tuberous sclerosis complex is estimated at between 0.7 – 8.8 per 100,000, and facial angiofibromas to be the most common presentation in tuberous sclerosis complex which are prevalent in 70-80% of people with tuberous sclerosis complex. The Committee noted in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>, that there could be 399 individuals in New Zealand with tuberous sclerosis complex (based on a 2004 estimate), and of that number, there may be 40-80 individuals in New Zealand with moderate/significant facial angiofibromas, with an additional seven new cases per year.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted those with facial angiofibromas associated with tuberous sclerosis complex can experience frequent spontaneous and uncontrolled bleeding, and infections are common when the lesions are present around the eyes, nose, and mouth. Due to progressive growth, over time facial angiofibromas can impair vision and breathing, and have psychological consequences (emotional, social and self-image disorders), with uncontrolled growth potentially causing further cosmetic disfigurement (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. Pediatr Dermatol. 2016; 33:518-25</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the number and size of the facial angiofibromas increased through childhood, whilst in adulthood the lesions tended to be stable or grow at a slower rate.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the effects of the condition were most distressing in young adults, and as such they had a higher health need.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a 2016 survey, undertaken in a children’s hospital, suggested that those who received treatment for facial angiofibromas reported a significantly improved Children’s Dermatology Life Quality Index (CDLQI) score compared to those not treated. The CDLQI score of untreated individuals was 9.5 compared to 3.83 in those who had received treatment (p=0.001). Those who were not treated had a CDLQI score that represented a moderate effect on quality of life, whilst those treated had a small effect (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).The largest proportion of those who were treated had been recommended to use topical rapamycin (47.3%) (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a US study provided by the supplier that reported gaps in the care for people with facial angiofibromas associated with tuberous sclerosis complex. 41% of people reported never receiving treatment for facial angiofibromas even though 74.3% had visited a dermatologist, indicating many people are unable to receive treatment. The Committee considered that underdiagnosis may also influence access to treatment in New Zealand for those affected, with the condition being hard to diagnose.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there is minimal access to dermabrasion or laser therapies in the public health system, these treatments must be self-funded by the individual at significant cost.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the health need of those with facial angiofibromas was higher than those on the body due to increased prominence of the angiofibromas, and the ensuing greater cosmetic impact.</p><p><br></p><p><em>Health benefit</em></p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus forms a complex which binds to and selectively inhibits mTORC1. The mTOR complex modulates aspects of the cell cycle, cell growth, proliferation and migration. mTORC1 inhibition reduces the dysregulated growth and differentiation observed in facial angiofibromas.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800048/"" target=""_blank"">Koenig et al, JAMA Dermatol. 2018;154:773-80</a> study of 179 individuals randomised to control, 0.1% or 1% topical treatment for 6 months, applied once daily. At 6 months the Angiofibroma Grading Scale mean improvement for 1% sirolimus was 16.7 points vs 11.0 for 0.1% sirolimus vs 2.1 points for vehicle only (P &lt; .001 for 1% and 0.1% vs vehicle only). The Committee noted there were minimal adverse events. The Committee considered most improvement was observed in the first month of treatment, with most participants completing the trial. The Committee noted there was no drug detected in the serum of individuals.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>Committee noted the <a href=""https://pharmconnect.lightning.force.com/lightning/r/Application__c/a0S2P0000032osgUAA/view"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2017;153:39-48</a> study that involved 36 people, of which 18 were children. Sirolimus gel concentrations of 0.05%, 0.1%, or 0.2% or placebo were applied twice daily for 12 weeks. The improvement factor was statistically significant in all active treatment groups receiving 0.2% sirolimus (mean [SD], 1.94 [0.68]; P &lt; .001) but not in the adult subgroups receiving 0.1% (mean [SD], 0.88 [0.85]; P = .31) and 0.05% (mean [SD], 1.63 [1.11]; P = .09) concentrations of sirolimus. No significant adverse effects were observed. The Committee considered that whilst the study was small, it was well designed.</p><p>11.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that low blood levels of sirolimus (&lt;0.25 ng/mL) were detected in adults (1 [25%] in 0.1% and 2 [50%] in 0.2%) and children (1 [25%] in 0.05%, 2 [50%] in 0.1%, and 4 [100%] in 0.2%). The Committee noted that the authors considered this may be due to the gel formulation being better absorbed than the ointment form.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800026/"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2018;154:781-788</a> study of 62 people, of which 27 were children, who were received either 0.2% sirolimus gel (n=30) or placebo (n=32) applied twice daily for 12 weeks. The response rates of the angiofibromas at weeks 4, 8, and 12 of treatment was 20% (95% CI, 8%-39%; P = .01), 43% (95% CI, 26%-63%; P &lt; .001), and 60% (95% CI, 41%-77%; P &lt; .001) with sirolimus vs 0% in placebo group. 0/ 31 in placebo group were rated improved or better, and 26 (84%) were rated unchanged. In the sirolimus group 5 (17%) and 13 (43%) were rated markedly improved and improved, respectively.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22309333/"" target=""_blank"">Foster et al, Australas J Dermatol. 2012;53:52-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692771/"" target=""_blank"">Wataya-Kaneda et al, Br J Dermatol. 2011;165:912-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Csoma et al, Pediatric Dermatology. 2019;36:S41-S42 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29270462/"" target=""_blank"">Amin et al, Int Sch Res Notices. 2017:8404378</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24359523/"" target=""_blank"">Tu et al, Australas J Dermatol. 2014;55:63-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21834948/"" target=""_blank"">Salido et al, J Eur Acad Dermatol Venereol. 2012;26:1315-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763637/"" target=""_blank"">Viswanath et al, Indian J Dermatol. 2016; 61: 119</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24136238/"" target=""_blank"">Bae-Harboe et al, Lasers Surg Med. 2013;45:555-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24355193/"" target=""_blank"">Knopfel et al, Actas Dermosifiliogr. 2014;105:802-3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Smith et al, BJD, 2012; 167 (s1); ppl127-141 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ott et al, Int J Clin Pharm, 2013, 35;1331 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23680945/"" target=""_blank"">Wheless et al, J Child Neurol, 2013, 28;933</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/"" target=""_blank"">Wheeless et al, Child Neurol Open. 2019; 6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22301052/"" target=""_blank"">Truchuelo et al, Dermatol Online J. 2012;18:15</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22250258/"" target=""_blank"">Wataya-Kaneda et al, Arch Dermatol. 2012;148:138-9</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21931059/"" target=""_blank"">DeKlotz et al, Arch Dermatol. 2011;147:1116-7</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20644030/"" target=""_blank"">Haemel et al. Arch Dermatol. 2010;146:715-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ejhp.bmj.com/content/23/Suppl_1/A207.2"" target=""_blank"">Trujillano Ruiz et al, EJH Pharmacy 2016;23:A207. </a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987392/"" target=""_blank"">Okanishi et al, Front Med (Lausanne). 2020; 7: 1.</a></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-family: Symbol;"">·</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"">Lee et al, Dermatology. 2018;234:13-22</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01417-5"" target=""_blank"">Hatano et al, Orphanet J Rare Dis. 2020;15:133</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32385845/"" target=""_blank"">Wataya-Kaneda et al, Dermatol Ther (Heidelb). 2020;10:635-650</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28181194/"" target=""_blank"">Ebrahimi-Fakhari et al, Dermatol Ther (Heidelb), 2017; 7:175–179</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29380350/"" target=""_blank"">Norrenberg et al, Br J Dermatol. 2018;179:208-209</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Safa et al, Oxford Medical Case Reports, 2017;7, 104–105 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28771801/"" target=""_blank"">Wang et al, Pediatr Dermatol. 2017;34:572-577.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23909960/"" target=""_blank"">Tanaka et al, Br J Dermatol. 2013;169:1314-8.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27643542/"" target=""_blank"">Cinar et al, Indian J Dermatol Venereol Leprol. 2017;83:27-32</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25790347/"" target=""_blank"">Pynn et al, Pediatr Dermatol. 2015;32:e120-3.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Hwang et al, Journal of Dermatology, 2012 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372909/"" target=""_blank"">Vasani et al, Indian J Dermatol. 2015; 60: 165–169.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24401865/"" target=""_blank"">Park et al, Dermatology 2014;228:37–41:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Rodrigo-Nicolas et al, J Am Acad Dermatol, 2013, P6521 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20673154/"" target=""_blank"">Kaufman Mcnamara et al, J Dermatolog Treat. 2012; 23: 46–48</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21861956/"" target=""_blank"">Valerón-Almazán P, et al, Actas Dermosifiliogr. 2012;103:165—6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28502378/"" target=""_blank"">Malissen et al, J Am Acad Dermatol. 2017;77:464-472.e3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692776/"" target=""_blank"">Mutizwa et al, Br J Dermatol. 2011;165:922-3</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32064596/"" target=""_blank"">Chen et al Br J Dermatol. 2020; 183:655-663</a></p><p>1.21.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered there to be a lack of long-term safety data (&gt;5 years) regarding the adverse effects of topical sirolimus.\xa0</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered it was unclear which types of lesions respond to topical sirolimus, but facial hypomelanotic macules and some fibrous cephalic plaques have been observed to respond to treatment.</p><p><br></p><p><em>Suitability</em></p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus is administered as a topical preparation, once daily, ideally prior to sleep. The amount of topical preparation that needs to be applied is 6 mg/cm2/day to produce a thin confluent layer on the affected skin. The recommended amount should be explained by a pharmacist or prescriber to ensure that an adequate amount is administered.</p><p><br></p><p><em>Cost and savings</em></p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that individuals were likely to need long term uninterrupted treatment to maintain the clinical benefit, with the Committee noting the condition had a lifelong health need. In practical use the Committee estimated that many people will cease use as their condition improves, restarting after a period off treatment as the condition recurs. The Committee estimated an average time on treatment as 50% across the entire group of people using sirolimus for facial angiofibromas.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the quantity of ointment used per week would be equal to their previous estimate for the 0.1% formulation, at 1-2g used per week. They considered that due to the higher strength, there is likely an efficacy gain over the 0.1% formulation.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted health benefit evidence that reported a reduction in application frequency from three times weekly to once weekly did not adequately address the health needs of the individual, with the condition worsening upon reduction in treatment.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that while some people would receive surgical treatment privately, this was uncommon in the public system.</p><p><br></p><p><em>Funding criteria</em></p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that funding of this treatment through the NPPA pathway should not be restricted during the funding assessment process.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for sirolimus if it were to be funded in New Zealand for facial angiofibromas associated with tuberous sclerosis complex. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AfkX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000czFN"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for sirolimus in the treatment of facial angiofibromas associated with tuberous sclerosis complex.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for sirolimus in the treatment of facial angiofibromas associated with tuberous sclerosis complex.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'fs': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkX2AS'}, 'Id': 'a0POZ000004AfkX2AS', 'Event_Date__c': '2023-11-29', 'Event_Description__c': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Nov 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that sirolimus be listed with a <strong>high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application — (Facial angiofibromas) </strong><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for life for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1. Patient has confirmed diagnosis of facial angiofibromas </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2. Patient has ongoing improvement in symptoms </span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>11.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee recommendation was based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of those with facial angiofibromas</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of other treatments available in the public system</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The need to ensure equitable access to treatment</p><p><br></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for sirolimus in the treatment of facial angiofibromas associated with tuberous sclerosis complex.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the impact of funding sirolimus for the treatment of facial angiofibromas associated with tuberous sclerosis complex on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that whilst there was no published evidence on the prevalence of the condition in Māori, approximately four of the 32 requests for access to sirolimus, for all indications, via the Named Patient Pharmaceutical Assessment (NPPA) process were for Māori. The Committee noted access to medicines via the NPPA process may result in inequitable access due to the physician time and resource required for an application.</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted its previous review (as the Dermatology Subcommittee) in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a> of an application for topical sirolimus consequent to NPPA applications for sirolimus ointment (rapamycin). That application involved a 0.1-1% ointment that was compounded by Optimus Healthcare compounding pharmacy. The Committee noted that the recommendation of deferral, subject to the outcome of a phase two study by Koenig et al on 177 patients with tuberous sclerosis complex associated facial angiofibromas treated with topical sirolimus (NCT01526356). This product was ranked in 2020. This application is now on the decline list due to the lack of a supplier, and the product not being able to be safely compounded in community pharmacy.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a further application for this pharmaceutical was received in January 2023, from a supplier for the same indication, but for a non-compounded product with a strength of 0.5%.</p><p><br></p><p><em>Health need</em></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need of those with facial angiofibromas associated with tuberous sclerosis complex in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted facial angiofibromas are the most common presentation in tuberous sclerosis complex and are prevalent in 70-80% of those with the condition.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted tuberous sclerosis complex is an autosomal dominant genetic disorder which is caused by a mutation in either the TSC1 gene or the TSC2 gene. It is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the prevalence of tuberous sclerosis complex is estimated at between 0.7 – 8.8 per 100,000, and facial angiofibromas to be the most common presentation in tuberous sclerosis complex which are prevalent in 70-80% of people with tuberous sclerosis complex. The Committee noted in <a href=""https://pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">November 2015</a>, that there could be 399 individuals in New Zealand with tuberous sclerosis complex (based on a 2004 estimate), and of that number, there may be 40-80 individuals in New Zealand with moderate/significant facial angiofibromas, with an additional seven new cases per year.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted those with facial angiofibromas associated with tuberous sclerosis complex can experience frequent spontaneous and uncontrolled bleeding, and infections are common when the lesions are present around the eyes, nose, and mouth. Due to progressive growth, over time facial angiofibromas can impair vision and breathing, and have psychological consequences (emotional, social and self-image disorders), with uncontrolled growth potentially causing further cosmetic disfigurement (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. Pediatr Dermatol. 2016; 33:518-25</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the number and size of the facial angiofibromas increased through childhood, whilst in adulthood the lesions tended to be stable or grow at a slower rate.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the effects of the condition were most distressing in young adults, and as such they had a higher health need.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a 2016 survey, undertaken in a children’s hospital, suggested that those who received treatment for facial angiofibromas reported a significantly improved Children’s Dermatology Life Quality Index (CDLQI) score compared to those not treated. The CDLQI score of untreated individuals was 9.5 compared to 3.83 in those who had received treatment (p=0.001). Those who were not treated had a CDLQI score that represented a moderate effect on quality of life, whilst those treated had a small effect (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).The largest proportion of those who were treated had been recommended to use topical rapamycin (47.3%) (<a href=""https://pubmed.ncbi.nlm.nih.gov/27436143/#:~:text=Abstract,leading%20to%20negative%20psychosocial%20outcomes."" target=""_blank"">Crall et al. 2016</a>).</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a US study provided by the supplier that reported gaps in the care for people with facial angiofibromas associated with tuberous sclerosis complex. 41% of people reported never receiving treatment for facial angiofibromas even though 74.3% had visited a dermatologist, indicating many people are unable to receive treatment. The Committee considered that underdiagnosis may also influence access to treatment in New Zealand for those affected, with the condition being hard to diagnose.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there is minimal access to dermabrasion or laser therapies in the public health system, these treatments must be self-funded by the individual at significant cost.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the health need of those with facial angiofibromas was higher than those on the body due to increased prominence of the angiofibromas, and the ensuing greater cosmetic impact.</p><p><br></p><p><em>Health benefit</em></p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus forms a complex which binds to and selectively inhibits mTORC1. The mTOR complex modulates aspects of the cell cycle, cell growth, proliferation and migration. mTORC1 inhibition reduces the dysregulated growth and differentiation observed in facial angiofibromas.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800048/"" target=""_blank"">Koenig et al, JAMA Dermatol. 2018;154:773-80</a> study of 179 individuals randomised to control, 0.1% or 1% topical treatment for 6 months, applied once daily. At 6 months the Angiofibroma Grading Scale mean improvement for 1% sirolimus was 16.7 points vs 11.0 for 0.1% sirolimus vs 2.1 points for vehicle only (P &lt; .001 for 1% and 0.1% vs vehicle only). The Committee noted there were minimal adverse events. The Committee considered most improvement was observed in the first month of treatment, with most participants completing the trial. The Committee noted there was no drug detected in the serum of individuals.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>Committee noted the <a href=""https://pharmconnect.lightning.force.com/lightning/r/Application__c/a0S2P0000032osgUAA/view"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2017;153:39-48</a> study that involved 36 people, of which 18 were children. Sirolimus gel concentrations of 0.05%, 0.1%, or 0.2% or placebo were applied twice daily for 12 weeks. The improvement factor was statistically significant in all active treatment groups receiving 0.2% sirolimus (mean [SD], 1.94 [0.68]; P &lt; .001) but not in the adult subgroups receiving 0.1% (mean [SD], 0.88 [0.85]; P = .31) and 0.05% (mean [SD], 1.63 [1.11]; P = .09) concentrations of sirolimus. No significant adverse effects were observed. The Committee considered that whilst the study was small, it was well designed.</p><p>11.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that low blood levels of sirolimus (&lt;0.25 ng/mL) were detected in adults (1 [25%] in 0.1% and 2 [50%] in 0.2%) and children (1 [25%] in 0.05%, 2 [50%] in 0.1%, and 4 [100%] in 0.2%). The Committee noted that the authors considered this may be due to the gel formulation being better absorbed than the ointment form.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/29800026/"" target=""_blank"">Wataya-Kaneda et al, JAMA Dermatol. 2018;154:781-788</a> study of 62 people, of which 27 were children, who were received either 0.2% sirolimus gel (n=30) or placebo (n=32) applied twice daily for 12 weeks. The response rates of the angiofibromas at weeks 4, 8, and 12 of treatment was 20% (95% CI, 8%-39%; P = .01), 43% (95% CI, 26%-63%; P &lt; .001), and 60% (95% CI, 41%-77%; P &lt; .001) with sirolimus vs 0% in placebo group. 0/ 31 in placebo group were rated improved or better, and 26 (84%) were rated unchanged. In the sirolimus group 5 (17%) and 13 (43%) were rated markedly improved and improved, respectively.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22309333/"" target=""_blank"">Foster et al, Australas J Dermatol. 2012;53:52-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692771/"" target=""_blank"">Wataya-Kaneda et al, Br J Dermatol. 2011;165:912-6.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Csoma et al, Pediatric Dermatology. 2019;36:S41-S42 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29270462/"" target=""_blank"">Amin et al, Int Sch Res Notices. 2017:8404378</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24359523/"" target=""_blank"">Tu et al, Australas J Dermatol. 2014;55:63-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21834948/"" target=""_blank"">Salido et al, J Eur Acad Dermatol Venereol. 2012;26:1315-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763637/"" target=""_blank"">Viswanath et al, Indian J Dermatol. 2016; 61: 119</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24136238/"" target=""_blank"">Bae-Harboe et al, Lasers Surg Med. 2013;45:555-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24355193/"" target=""_blank"">Knopfel et al, Actas Dermosifiliogr. 2014;105:802-3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Smith et al, BJD, 2012; 167 (s1); ppl127-141 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ott et al, Int J Clin Pharm, 2013, 35;1331 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23680945/"" target=""_blank"">Wheless et al, J Child Neurol, 2013, 28;933</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589944/"" target=""_blank"">Wheeless et al, Child Neurol Open. 2019; 6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22301052/"" target=""_blank"">Truchuelo et al, Dermatol Online J. 2012;18:15</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/22250258/"" target=""_blank"">Wataya-Kaneda et al, Arch Dermatol. 2012;148:138-9</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21931059/"" target=""_blank"">DeKlotz et al, Arch Dermatol. 2011;147:1116-7</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20644030/"" target=""_blank"">Haemel et al. Arch Dermatol. 2010;146:715-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ejhp.bmj.com/content/23/Suppl_1/A207.2"" target=""_blank"">Trujillano Ruiz et al, EJH Pharmacy 2016;23:A207. </a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987392/"" target=""_blank"">Okanishi et al, Front Med (Lausanne). 2020; 7: 1.</a></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-family: Symbol;"">·</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"" style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</a><a href=""https://pubmed.ncbi.nlm.nih.gov/29925060/"" target=""_blank"">Lee et al, Dermatology. 2018;234:13-22</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01417-5"" target=""_blank"">Hatano et al, Orphanet J Rare Dis. 2020;15:133</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32385845/"" target=""_blank"">Wataya-Kaneda et al, Dermatol Ther (Heidelb). 2020;10:635-650</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28181194/"" target=""_blank"">Ebrahimi-Fakhari et al, Dermatol Ther (Heidelb), 2017; 7:175–179</a>:</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29380350/"" target=""_blank"">Norrenberg et al, Br J Dermatol. 2018;179:208-209</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Safa et al, Oxford Medical Case Reports, 2017;7, 104–105 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28771801/"" target=""_blank"">Wang et al, Pediatr Dermatol. 2017;34:572-577.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23909960/"" target=""_blank"">Tanaka et al, Br J Dermatol. 2013;169:1314-8.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27643542/"" target=""_blank"">Cinar et al, Indian J Dermatol Venereol Leprol. 2017;83:27-32</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25790347/"" target=""_blank"">Pynn et al, Pediatr Dermatol. 2015;32:e120-3.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Hwang et al, Journal of Dermatology, 2012 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372909/"" target=""_blank"">Vasani et al, Indian J Dermatol. 2015; 60: 165–169.</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24401865/"" target=""_blank"">Park et al, Dermatology 2014;228:37–41:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Rodrigo-Nicolas et al, J Am Acad Dermatol, 2013, P6521 (supplier provided)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20673154/"" target=""_blank"">Kaufman Mcnamara et al, J Dermatolog Treat. 2012; 23: 46–48</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21861956/"" target=""_blank"">Valerón-Almazán P, et al, Actas Dermosifiliogr. 2012;103:165—6:</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol; color: windowtext;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28502378/"" target=""_blank"">Malissen et al, J Am Acad Dermatol. 2017;77:464-472.e3</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/21692776/"" target=""_blank"">Mutizwa et al, Br J Dermatol. 2011;165:922-3</a>.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32064596/"" target=""_blank"">Chen et al Br J Dermatol. 2020; 183:655-663</a></p><p>1.21.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered there to be a lack of long-term safety data (&gt;5 years) regarding the adverse effects of topical sirolimus.\xa0</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered it was unclear which types of lesions respond to topical sirolimus, but facial hypomelanotic macules and some fibrous cephalic plaques have been observed to respond to treatment.</p><p><br></p><p><em>Suitability</em></p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted sirolimus is administered as a topical preparation, once daily, ideally prior to sleep. The amount of topical preparation that needs to be applied is 6 mg/cm2/day to produce a thin confluent layer on the affected skin. The recommended amount should be explained by a pharmacist or prescriber to ensure that an adequate amount is administered.</p><p><br></p><p><em>Cost and savings</em></p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that individuals were likely to need long term uninterrupted treatment to maintain the clinical benefit, with the Committee noting the condition had a lifelong health need. In practical use the Committee estimated that many people will cease use as their condition improves, restarting after a period off treatment as the condition recurs. The Committee estimated an average time on treatment as 50% across the entire group of people using sirolimus for facial angiofibromas.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the quantity of ointment used per week would be equal to their previous estimate for the 0.1% formulation, at 1-2g used per week. They considered that due to the higher strength, there is likely an efficacy gain over the 0.1% formulation.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted health benefit evidence that reported a reduction in application frequency from three times weekly to once weekly did not adequately address the health needs of the individual, with the condition worsening upon reduction in treatment.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that while some people would receive surgical treatment privately, this was uncommon in the public system.</p><p><br></p><p><em>Funding criteria</em></p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that funding of this treatment through the NPPA pathway should not be restricted during the funding assessment process.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for sirolimus if it were to be funded in New Zealand for facial angiofibromas associated with tuberous sclerosis complex. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AfkX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000czFN"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000004Hb0uYAC'}, 'change': None}]",Mar 2023,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkV2AS'}, 'Id': 'a0POZ000004AfkV2AS', 'Event_Date__c': '2023-09-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001tPMzYAM'}, 'change': None}]",Sep 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000004AfkW2AS'}, 'Id': 'a0POZ000004AfkW2AS', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnvHYAQ'}, 'change': None}]",Sep 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
